Ferumoxytol

Summary

Ferumoxytol (CHEMBL1201867) is an approved unknown; indicated across 18 conditions including anemia and chronic kidney disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• Indications: 18 conditions
• Clinical trials: 78

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201867
Name	Ferumoxytol
Type	Unknown
Max phase	4

Also known as: CODE 7228, CODE-7228, Feraheme, Ferumoxytol, RIENSO, Rienso, FERUMOXYTOL

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

18 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
anemia	4	MONDO:0002280	EFO:0004272
chronic kidney disease	4	MONDO:0005300	EFO:0003884
iron deficiency anemia	3	MONDO:0001356	HP:0001891
coronary artery disorder	3	MONDO:0005010	EFO:0001645
AIDS dementia complex	2	MONDO:0020689	EFO:0002608
non-small cell lung carcinoma	2	MONDO:0005233	EFO:0003060
glioblastoma	2	MONDO:0018177	EFO:0000519
nervous system disorder	2	MONDO:0005071	EFO:0000618
temporal lobe epilepsy	2	MONDO:0005115	EFO:0000773
lung carcinoma	2	MONDO:0005138	EFO:0001071
neoplasm	1	MONDO:0005070	EFO:0000616
multiple sclerosis	1	MONDO:0005301	MONDO:0005301
urinary bladder neoplasm	0	MONDO:0004987	EFO:0000294
chronic progressive multiple sclerosis	0	MONDO:0005284	EFO:0003840
interstitial cystitis	0	MONDO:0018301	EFO:0008507
secondary progressive multiple sclerosis	0	MONDO:0000450	EFO:0008522

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 78.

Phase distribution

Phase	Trials
Not specified	18
PHASE2	15
PHASE3	14
PHASE1	11
EARLY_PHASE1	9
PHASE4	8
PHASE1/PHASE2	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04278651	PHASE4	RECRUITING	Early Antenatal Support for Iron Deficiency Anemia
NCT01148745	PHASE4	COMPLETED	Iron Indices and Intravenous Ferumoxytol: Time to Steady State
NCT01227616	PHASE4	COMPLETED	Compare Efficacy/Safety of Repeat Doses of Ferumoxytol With Iron Sucrose in CKD Subjects With IDA and on Hemodialysis
NCT01942460	PHASE4	COMPLETED	Ferumoxytol for Iron-Deficiency Anemia in Chronic Kidney Disease and Peritoneal Dialysis Patients
NCT02752191	PHASE4	COMPLETED	Feraheme As An MRI Contrast Agent For Pediatric Congenital Heart Disease
NCT04080908	PHASE4	TERMINATED	Study to Assess Feasibility and Safety of Iron Repletion With Feraheme in Iron Deficient Patients With Durable Ventricular Assist Device Support
NCT04205266	PHASE4	UNKNOWN	IV Iron vs Oral Iron for Treatment of Anemia in Women With Abnormal Uterine Bleeding
NCT05515874	PHASE4	COMPLETED	Predicting Stroke Risk in ICAD With Novel MRI
NCT03619850	PHASE3	RECRUITING	A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
NCT03893045	PHASE3	RECRUITING	A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects
NCT04268849	PHASE3	RECRUITING	Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
NCT07461948	PHASE3	RECRUITING	Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients
NCT01114139	PHASE3	COMPLETED	A Trial Comparing Ferumoxytol With Placebo for the Treatment of Iron Deficiency Anemia
NCT01114204	PHASE3	COMPLETED	A Trial Comparing Ferumoxytol With Iron Sucrose for the Treatment of Iron Deficiency Anemia
NCT01114217	PHASE3	COMPLETED	A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia
NCT01155375	PHASE3	TERMINATED	A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease
NCT01155388	PHASE3	TERMINATED	A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Nondialysis-Dependent Chronic Kidney Disease
NCT01264679	PHASE3	TERMINATED	A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease
NCT02319278	PHASE2/PHASE3	COMPLETED	DEtection of Cellular Inflammation With FERumoxytol in the HEART
NCT02694978	PHASE3	COMPLETED	A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)
NCT02954510	PHASE3	UNKNOWN	Ferumoxytol-enhanced Magnetic Resonance Imaging
NCT03657433	PHASE3	COMPLETED	Intravenous Infusions of Ferumoxytol Compared to Oral Ferrous Sulfate for the Treatment of Anemia in Pregnancy
NCT06348524	PHASE3	TERMINATED	Ferumoxytol-enhanced Magnetic Resonance Imaging
NCT01542879	PHASE1/PHASE2	RECRUITING	Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
NCT03270059	PHASE2	RECRUITING	Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System
NCT05340465	PHASE2	RECRUITING	Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants
NCT06483061	PHASE2	RECRUITING	Enhanced MRI Imaging in Healthy Participants and Participants With Epilepsy
NCT07452250	PHASE2	RECRUITING	Ferumoxytol-enhanced Magnetic Resonance Venography in Patients With Venous Diseases
NCT00659126	PHASE2	TERMINATED	Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors
NCT00659776	PHASE2	TERMINATED	MR, Histologic And EM Imaging Of Intravenous Ferumoxytol In Central Nervous System (CNS) Inflammation
NCT00707876	PHASE2	COMPLETED	Magnetic Resonance Angiography for Peripheral Arterial Disease (PAD)
NCT01052779	PHASE2	COMPLETED	A Trial Comparing Ferumoxytol to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Adult Subjects With Chronic Kidney Disease
NCT01336803	PHASE2	COMPLETED	Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI
NCT02141490	PHASE2	COMPLETED	Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers
NCT02189889	PHASE1/PHASE2	TERMINATED	Active Preoperative Anemia Management in Patients Undergoing Cardiac Surgery
NCT02499354	PHASE2	COMPLETED	Pilot Study: Randomized, Placebo-controlled Comparator Trial of IV vs Oral Iron Treatment of RLS With IDA. (IVOR-IDA)
NCT02678767	PHASE2	COMPLETED	Ferumoxytol-enhanced Imaging and Mapping in neuroAIDS
NCT03234309	PHASE2	WITHDRAWN	Ferumoxytol in Magnetic Resonance Imaging of Pediatric Patients With Brain Tumors
NCT03325166	PHASE2	TERMINATED	Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases
NCT03347617	PHASE2	TERMINATED	Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).